Fmr LLC Buys 8,114 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Fmr LLC boosted its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 330.6% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,568 shares of the medical instruments supplier’s stock after buying an additional 8,114 shares during the period. Fmr LLC’s holdings in LeMaitre Vascular were worth $982,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. grew its stake in LeMaitre Vascular by 6.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 191,511 shares of the medical instruments supplier’s stock valued at $17,789,000 after acquiring an additional 11,395 shares during the period. Nicholas Investment Partners LP bought a new stake in LeMaitre Vascular during the 2nd quarter valued at $3,900,000. Creative Planning raised its holdings in LeMaitre Vascular by 20.7% during the third quarter. Creative Planning now owns 3,594 shares of the medical instruments supplier’s stock worth $334,000 after buying an additional 617 shares during the last quarter. Copeland Capital Management LLC lifted its stake in shares of LeMaitre Vascular by 1.0% in the third quarter. Copeland Capital Management LLC now owns 1,163,392 shares of the medical instruments supplier’s stock valued at $108,068,000 after buying an additional 11,318 shares in the last quarter. Finally, Portside Wealth Group LLC acquired a new position in shares of LeMaitre Vascular during the third quarter valued at about $497,000. 84.64% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. Cantor Fitzgerald assumed coverage on shares of LeMaitre Vascular in a research report on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 price target on the stock. StockNews.com downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday. Oppenheimer reissued an “outperform” rating and issued a $93.00 price target (up from $90.00) on shares of LeMaitre Vascular in a research report on Friday, November 1st. Barrington Research lifted their price objective on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a report on Friday, November 1st. Finally, JMP Securities increased their target price on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a report on Tuesday, August 20th. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $94.57.

Insider Transactions at LeMaitre Vascular

In other LeMaitre Vascular news, Director Bridget A. Ross sold 3,750 shares of the business’s stock in a transaction on Friday, November 15th. The shares were sold at an average price of $101.47, for a total transaction of $380,512.50. Following the sale, the director now owns 2,278 shares of the company’s stock, valued at $231,148.66. The trade was a 62.21 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 10.79% of the stock is owned by corporate insiders.

LeMaitre Vascular Price Performance

NASDAQ LMAT opened at $92.10 on Tuesday. The business’s fifty day moving average is $97.65 and its 200-day moving average is $89.62. The stock has a market capitalization of $2.07 billion, a price-to-earnings ratio of 51.20, a PEG ratio of 2.47 and a beta of 0.93. LeMaitre Vascular, Inc. has a one year low of $52.88 and a one year high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Thursday, October 31st. The medical instruments supplier reported $0.49 EPS for the quarter, topping the consensus estimate of $0.44 by $0.05. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The business had revenue of $54.82 million for the quarter, compared to analyst estimates of $53.50 million. During the same quarter in the previous year, the firm posted $0.33 earnings per share. The company’s revenue for the quarter was up 15.6% on a year-over-year basis. Research analysts expect that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, December 5th. Stockholders of record on Thursday, November 21st were given a dividend of $0.16 per share. The ex-dividend date was Thursday, November 21st. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.69%. LeMaitre Vascular’s dividend payout ratio is presently 34.97%.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.